Does biomarker use in oncology improve clinical trial failure risk? A large‐scale analysis

PURPOSE: To date there has not been an extensive analysis of the outcomes of biomarker use in oncology. METHODS: Data were pooled across four indications in oncology drawing upon trial outcomes from www.clinicaltrials.gov: breast cancer, non‐small cell lung cancer (NSCLC), melanoma and colorectal ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, Jayson L., Kuzulugil, Sebnem S., Pereverzev, Kirill, Mac, Stephen, Lopes, Gilberto, Shah, Zain, Weerasinghe, Ashini, Rubinger, Daniel, Falconi, Adam, Bener, Ayse, Caglayan, Bora, Tangri, Rohan, Mitsakakis, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957156/
https://www.ncbi.nlm.nih.gov/pubmed/33620160
http://dx.doi.org/10.1002/cam4.3732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957156/
https://www.ncbi.nlm.nih.gov/pubmed/33620160
http://dx.doi.org/10.1002/cam4.3732

Ejemplares similares